INTS (47) INAB (38) ATYR (44) BCDA (49) ⌘ Pro Terminal →

Passage Bio Inc. (PASG) — RQD Stock Rating Cockpit

$3.52 +5.71% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Passage Bio Inc. (PASG) carries a Roarable Rating of D (Sell) with 51/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $11.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-3.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PASG)Realized 20D OHLCV Swing Band: ±12.5%

RSI-14 MOMENTUMNEUTRAL RANGE

38.630 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

3 / 99-Pt Accounting

52-WEEK LASER RANGE2% OF RANGE

L: $3$3.52H: $20

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 18 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: CRQD 25 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on PASG

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (40)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (55)

18/40 institutional & smart-money positioning score with 15/20 macro alignment.

Bull Case: Why Buyers Like PASG

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PASG)

✓Walkthrough of PASG's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PASG // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -31.12%🛡️ HOLDING TREND SUPPORT

2026-10-30O $3.48H $3.61L $3.44C $3.52VOL 7.2K

RES: $4.70SUP: $3.27SMA50: $4.27SMA200: $6.25

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PASG Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PASG Butterfly Map → + Track PASG →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PASG today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PASG. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PASG today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PASG)

Health Care Rank #339 of 1016 ⚔️ INTS vs PASG Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PASG vs. INTS, INAB, ATYR, BCDA)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Passage Bio Inc. (PASG) ranks #339 by composite RQD confidence (51/100, grade D) and #886 by equity capitalization ($11.3M). Within this direct 5-issuer industry benchmark cohort, PASG leads on earnings valuation at N/A trailing P/E, while PASG leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PASG currently leads its immediate peer cohort in composite quantitative strength at 51/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PASG ACTIVE Passage Bio Inc.	D	51/100	—	—	-35.0%	+5.71%	$11.3M	Benchmark Subject
INTS Intensity Therapeutics Inc.	D	47/100	—	—	-35.0%	-1.18%	$10.9M	/ints-vs-pasg →
INAB IN8bio Inc.	D-	38/100	—	—	-35.0%	-3.91%	$9.7M	/inab-vs-pasg →
ATYR aTyr Pharma Inc.	D	44/100	—	—	-35.0%	+4.56%	$13.5M	/atyr-vs-pasg →
BCDA BioCardia Inc.	D	49/100	—	—	-35.0%	-2.26%	$14.0M	/bcda-vs-pasg →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001787297

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Passage Bio Inc. (PASG) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$45.5M, operating cash flow of -$31.5M, and free cash flow of -$31.5M (+34.3% YoY). On the balance sheet, PASG closed FY2025 with $62.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$45.5M	-$31.5M	-$31.5M	$62.3M	—
FY2024 (FY)	2024-12-31	$0	-$64.8M	-$48.0M	-$48.0M	$102.4M	—
FY2023 (FY)	2023-12-31	$0	-$102.1M	-$78.3M	-$78.3M	—	—

3. PASG Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PASG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Passage Bio Inc. (NASDAQ: PASG) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $3.52 (+5.71% 1D, market cap $11.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, PASG ranks #339 in composite RQD confidence.

How does PASG compare to INTS and INAB in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), PASG carries a Roarable D (51/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, INTS (Intensity Therapeutics Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $10.9M) and INAB (IN8bio Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $9.7M). Among the 5-stock peer group, PASG leads on earnings multiple (N/A) while PASG leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PASG?

Per PASG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001787297), Passage Bio Inc. generated $0 in revenue, -$45.5M in net income, and -$31.5M in free cash flow against $62.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PASG trading relative to its 50-day, 200-day, and 52-week technical levels?

PASG last traded at $3.52 (+5.71% on volume of 16,689 shares), positioning the stock -17.56% below its 50-day simple moving average ($4.27) and -43.68% below its 200-day simple moving average ($6.25). Across its 52-week range of $3.29 to $20.00, PASG sits at the 1.4% percentile with a 14-day RSI of 38.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.08 to $3.96).

PASG Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell PASG stock right now?

Passage Bio Inc. (PASG) currently earns a Roarable Rating of D (Sell — SELL) with 51/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is PASG's 12-month price target and RQD AI Jury consensus?

PASG's 12-month base price target is $3.41 (range $2.66 to $21), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: PASG RQD Cockpit PASG 12M Forecast PASG Earnings & Move PASG Dividends & DRIP PASG Insiders & 13F PASG Whale Options PASG Profit Sankey PASG News & Why